Shares of Iterum Therapeutics PLC (NASDAQ:ITRM) have earned a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $19.00.
Several research firms have recently weighed in on ITRM. Zacks Investment Research upgraded shares of Iterum Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 price objective on the stock in a research report on Thursday, March 28th. Royal Bank of Canada lowered their price objective on shares of Iterum Therapeutics to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 15th. Finally, Needham & Company LLC restated a “buy” rating and set a $20.00 price objective on shares of Iterum Therapeutics in a research report on Monday, March 25th.
NASDAQ ITRM opened at $6.45 on Thursday. Iterum Therapeutics has a 1 year low of $4.70 and a 1 year high of $13.00. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.36 and a current ratio of 4.36. The company has a market capitalization of $90.04 million and a price-to-earnings ratio of -0.91.
Iterum Therapeutics Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Featured Story: Stock Split
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.